63results about How to "Suitable for process production" patented technology

The invention discloses an immunomodulator slow-release preparation and a preparation method thereof. A lenalidomide slow-release tablet is composed of a slow-release layer and an optional quick-release layer, wherein the slow-release layer contains active ingredients of lenalidomide and a slow-release framework material simultaneously; the quick-release layer does not contain the slow-release framework material. The lenalidomide slow-release tablet disclosed by the invention is capable of slowly and uniformly releasing medicines by virtue of the slow-release framework material, so as to reduce the release speed, delay the time to peak, prolong the action time of lenalidomide, and provide a uniform and constant blood concentration. Moreover, The lenalidomide slow-release tablet disclosed by the invention is simple in prescription and excellent in quality stability; the preparation process is simple to operate, free from special treatment and production equipment, low in production cost, and beneficial to batch-enlarged industrial production for the product; the preparation method is high in yield, the granulation and crushing procedures are simple and practicable to operate, the intermediate material is good in stability, flowability, compressibility and content uniformity, and completely meets the requirements of tabletting, and the surface of the prepared tablet is smooth and beautiful.

The invention belongs to the field of lithium ion batteries, and particularly relates to a high-rate lithium ion battery graphite cathode material and a preparation method thereof. The preparation method comprises the following steps: (1) pulverization and shaping of raw materials; (2) graphitization; (3) demagnetization screening; (4) liquid phase coating granulation; (5) surface oxidation treatment. According to the high-rate lithium ion battery graphite cathode material and the preparation method thereof, a liquid phase coating granulation process replaces traditional secondary granulationthrough optimized fine graphite, so as to realize uniform coating of the surface of graphite, reduce the anisotropism of the graphite and shorten the diffusion path of lithium ions; then a micro porestructure is formed on the surface of the graphite through a surface oxidization pore formation process, so that a lithium ion migration channel of a cardinal plane is added to increase the migrationspeed of lithium ions. The charging rate of the graphite obtained by the method is more than 8 C, and the capacity can be maintained at 80 percent or above under the discharging rate more than 30 C.

The invention discloses a synthetic method of bempedoic acid. The method comprises the following steps of: taking isobutyronitrile (ester) as a starting raw material, carrying out reaction with 2, 5-dibromopentane under the catalysis of alkali to generate 7-bromo-2, 2-dimethylheptonitrile (ester), then forming a Grignard reagent with magnesium, carrying out reaction with formate to generate 8-hydroxy-2, 2, 14, 14-tetramethylpentadecane dinitrile (ester), and finally carrying out alkaline hydrolysis and acidification to obtain bempedoic acid. The synthetic route is short, all the used raw materials are easy to obtain, the cost is low, the yield of each step of reaction is high, and the purity is high, therefore the method is suitable for industrial production.

The invention discloses a 6-halogenated glucose C-glycoside as well as a preparation method and application thereof. A structure of 6-halogenated glucose C-glycoside is shown in formula I; an intermediate can be synthesized efficiently with cheap and easily available raw materials; meanwhile, when the raw material is used for synthesizing Jardiance, dapagliflozin and the like, a reaction yield ishigh, and an obtained product has high purity and relatively high industrial application prospect.

The invention discloses a polymouphous substance II of imatinib mesylate, and also discloses a preparation method for the polymouphous substance and a medicinal composition of the polymouphous substance.

The invention relates to a method for synthesizing 1,1,2,2-tetrafluoroethane, which belongs to the field of preparation of refrigerants. TFE-containing mixed gas and hydrogen pass through a porous carrier supported hydrogenation catalyst bed to generate HFC-134; the TFE-containing mixed gas is a mixture formed by TFE and inert gas; the inert gas is gas which does not react with the TFE and the hydrogen under reaction conditions; and a porous carrier material is fluoride or oxyfluoride. An inert component in the method does not participate in the reaction, but can take away the heat generated by the reaction to ensure that the temperature of the catalyst bed is relatively steady and the service life of a catalyst is prolonged; and the adopted porous carrier is the fluoride or the oxyfluoride, does not react with hydrogen fluoride removed during the reaction, improves the service life of the catalyst and is easy to recycle at the same time. The synthesis method has good stability and safe synthesis process, and is suitable for technologized production.

The invention relates to a dopamine prodrug composition and a preparation method of the dopamine prodrug composition. The invention provides a pharmaceutical composition of dopamine prodrug, and the composition comprises the dopamine prodrug, benserazide hydrochloride, an adhesive, a stabilizer and a pharmaceutically acceptable carrier. The pharmaceutical composition containing the dopamine prodrug provided by the invention has excellent stability and does not occur color change, and is capable of effectively guaranteeing that the product quality meets a quality standard requirement within a storage period. The pharmaceutical composition containing the dopamine prodrug provided by the invention has a simple prescription, and auxiliary materials are cheap and available with a small amount; the preparation process provided by the invention is simple and easy to control, used devices are the most conventional workshop production devices, the cost is low, and the preparation process is suitable for industrial production.

The invention discloses an extraction method of silibinin. The extraction method includes following steps: (1), washing silibinin to be extracted, draining water, and performing microwave drying to enable moisture in silibinin to be lowered to below 10%; (2), adding ethyl acetate to dissolve silibinin, extracting total flavone, and collecting ketone in vacuum; (3), adding water to dissolve total flavones to obtain precipitate, adding alcohol solution for dissolving to obtain a silibinin coarse product, adopting acetone as a solvent, adding the silibinin coarse product, heating for dissolving,and heating till backflow; (4), performing acid pickling on saturated macroporous resin and alcohol washing sequentially to obtain alcohol solution of silibinin; (5), cooling and stirring for crystallization, stirring, filtering, washing with 95% alcohol, draining, and drying a filter cake to obtain a silibinin finished product; (6), performing secondary vacuum drying and concentrating to obtain refined silibinin. The extraction method is simple, efficient, free of harmful and toxic solvent residue, high in product purity, environment-friendly and suitable for industrial production.

The invention discloses a method used for preparing mecobalamin. The method comprises: dissolving cyanocobalamin, butanone and cobalt chloride hexahydrate in purified water, adding a sodium borohydride solution drop by drop for a reduction reaction, adding trimethylsulfoxonium iodide drop by drop for a methylation reaction to generate mecobalamin, and refining mecobalamin through a crystallizationmethod to obtain high-purity mecobalamin. The provided method is simple and easy, is simple to operate, complete in reaction, mild in condition, high in yield and high in purity, and is particularlysuitable for massive production.

The invention belongs to the technical field of food processing and in particular relates to a production technology of black soybean vinegar. The production technology comprises the following steps:firstly, weighing a black soybean mixture, wheat, sorghum rice, peas, smashed bran, cavings and yeast for making hard liquor in proportion; secondly, putting black soybeans, the wheat, the sorghum rice, the peas, the smashed bran and the cavings into a steamer, and steaming for 120 minutes; thirdly, putting cooked raw materials into a fermentation tank, spreading out and cooling, then pouring intothe yeast for making the hard liquor and stirring, and then carrying out constant temperature fermentation for 15 days; fourthly, putting the fermented raw materials into a smoke baking tank, and carrying out smoke baking for 15 days; and fifthly, pouring vinegar on the raw materials subjected to the smoke baking, and then carrying out grooving and grouting conservation or bottling by virtue of apipeline. The production technology provided by the invention has the advantages that the problem that the black soybeans can not be fully released in the prior art is solved, and a black soybean vinegar soaking technology can be effectively replaced, so that dissolution of nutrient substances of the black soybeans can be effectively enhanced, and taste and flavor are also improved.

The invention discloses a high-capacity pulse-activating injection and a preparation method thereof. The preparation method comprises the following steps of with red ginseng, radix ophiopogonis and schisandra chinensis as raw materials, preparing by using a modern extracting and purifying method to obtain an active part with high effective ingredient content and low impurity component content; then, adding glucose or sodium chloride; and diluting the active part into the injection with the specification of 100-500ml by using water for injection. The high-capacity pulse-activating injection provided by the invention can be directly used for infusion, can be used for avoiding secondary pollution during liquid preparation, and is particularly good in stability and high in safety performance in clinic application; and the preparation method is reasonable in process design and suitable for large-scale industrial production.

The invention discloses a new crystal of rivaroxaban and a preparation method thereof. The new crystal of rivaroxaban is crystal SMN-F, X-ray powder diffraction spectrum of which has diffraction peaks when a diffraction angle 2theta is 3.7+/-0.2, 7.3+/-0.2, 14.5+/-0.2, 21.8+/-0.2, 29.2+/-0.2, 31.9+/-0.2 and 33.5+/-0.2. The preparation method of the rivaroxaban SMN-F crystal provided by the invention has the advantages of simple process, short time, and suitability for technological production, etc. At the same time, the rivaroxaban SMN-F crystal prepared by the method provided by the invention has the advantages of high purity, fast dissolution rate and good solubility, etc.

The invention discloses melittin and a separation and purification method thereof, and relates to the technical field of biology. The method comprises the following steps: carrying out primary reversed-phase C18 semi-preparative column separation on a bee venom crude extract to be separated and purified, carrying out gradient elution by taking a formic acid aqueous solution and acetonitrile as mobile phases, collecting an eluent, then freeze-drying the eluent, redissolving, and carrying out secondary reversed-phase C18 semi-preparative column separation on the redissolved solution, in the secondary reversed-phase C18 semi-preparative column separation, a trifluoroacetic acid aqueous solution and methanol are used as mobile phases for isocratic elution. The method can achieve the technical effects of high separation purity, less target substance loss and less organic solvent dosage without combining with an ultrafiltration process for impurity removal in a specific pH environment, and has the technical advantages of environmental friendliness, simple device, simplicity and convenience in process operation and suitability for industrial production.

The invention belongs to the technical field of medicinal chemistry, and particularly relates to a novel intermediate of palbociclib, namely 4-(6-(8-cyclopentyl-5-methyl-7-oxo-6-(1-propoxyvinyl)-7,8-dihydropyrido[2, 3-d]pyrimidin-2-ylamino)pyridin-3-yl)-piperazinyl-1-carboxylic acid tert-butyl ester, and a crystal form and a preparation method of the novel intermediate. The method is simple in technological operation and post-treatment, a crystallization solvent is easy to recycle, cost is low, and the obtained intermediate is easy to crystallize, good in stability, good in purity, high in yield and more suitable for industrial production.

The invention provides a sheep embryo gelatin health food comprising the following constituents of: animal skin gelatin, gelatin, a sheep embryo enzyme hydrolysate, edible sugar, yellow wine and edible vegetable oil, wherein the weight ratio of the animal skin gelatin to the gelatin to the sheep embryo enzyme hydrolysate is (8-12):(2-6):1, the content of amino acid nitrogen in the sheep embryo enzyme hydrolysate is (2-20)g/100ml, and the intrinsic viscosity Eta of the animal skin gelatin is (10-6)dL/g. The obtained health food contains abundant amino acids and some elements which facilitate the absorption by the body and are good for human health, can be used for regulating the body balance better, improving the circulation and preventing the arteriosclerosis, has a high effect of beauty and curative effects on a coronary heart disease and an ischemic brain disease, and also is suitable for critically ill patients such as a diabetic patient, a kidney patient and the like to take a high-quality high-protein health food.

The invention relates to 7-ethyl-10-hydroxycamptothecine crystal forms II and III, and a preparation method and application thereof. The crystal form II uses Cu-K alpha radiation; the X-ray powder diffraction represented by 2theta angle has characteristic peaks when the diffraction angle is 5.64, 10.80, 12.55, 13.48, 17.09, 17.65, 18.21, 18.79, 24.52 and 26.84 degrees; and the error range of 2theta is +/-0.2 degree. The crystal form III uses Cu-K alpha radiation; the X-ray powder diffraction represented by 2theta angle has characteristic peaks when the diffraction angle is 4.58, 9.34, 10.42, 11.12, 12.30, 13.40, 14.40, 16.34, 16.86, 17.20, 17.70, 18.72, 19.32, 21.48, 22.44, 24.90, 25.40, 25.68 and 27.44 degrees; and the error range of 2theta is +/-0.2 degree. The two crystal forms of 7-ethyl-10-hydroxycamptothecine have high solubility and favorable stability.